The Food and Drug Administation is approving a generic drug for a very rare genetic disorder, but not for autism. On Tuesday, the U.S. agency said the drug helps children and adults who cannot get enough folate into the brain. That's a major turnaround from announcements made at a White House news conference in September. At that event, President Donald Trump and the FDA commissioner said the drug was under review for approval in patients with autism. FDA officials say they narrowed the review to the strongest evidence. They say that evidence supports use only in patients with a specific genetic mutation.

The Trump administration is set to launch TrumpRx, a website to help patients buy prescription drugs directly from manufacturers at discounted rates. White House press secretary Karoline Leavitt announced Thursday's expected unveiling in a social media post. The website is not a purchasing platform but directs users to drugmakers' own sites. President Trump first mentioned TrumpRx in September, highlighting deals with pharmaceutical companies to lower drug prices. The website's release faced delays, but it now showcases efforts to reduce costs through agreements with major companies like Pfizer and AstraZeneca. However, the actual savings for consumers remain unclear.

The Trump administration says pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations and that it's expected to produce billions in savings for older adults. But the net prices unveiled Tuesday aren't what Medicare recipients will pay at their pharmacy counters because those final amounts will depend on each individual's plan and how much they spend annually on prescriptions. Health Secretary Robert F. Kennedy Jr. touted the deals as part of efforts to address affordability concerns. The negotiation program is mandated by law and began under the Biden administration.

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with President Donald Trump's administration. Trump made the announcement Tuesday with Pfizer CEO Albert Bourla at the White House. Under the agreement, New York-based Pfizer will charge most-favored-nation pricing to Medicaid and guarantee the same pricing on newly launched drugs. That involves matching the lowest price offered in other developed nations. The agreement by Pfizfer builds on an executive order Trump signed in May setting a deadline for drugmakers to electively lower prices or face new limits on what the government will pay.

Pricey prescriptions and nagging medical costs are swamping some insurers and employers, which means patients may start paying more next year. Health insurance will grow more expensive in many corners of the market in 2026, and some coverage may shrink. That could leave patients exposed to more costs for doctor visits and prescription coverage changes. Price changes could be especially stark in individual coverage marketplaces, where insurers also are predicting the end of some government support that helps people buy coverage. Expensive gene therapies and diabetes and obesity treatments are pressuring prescription coverage.

President Donald Trump has signed an executive order setting a 30-day deadline for drugmakers to lower the cost of prescription drugs in the U.S. or face new limits down the road over what the government will pay. The Republican president's order Monday calls on the health department to broker new price tags for drugs. If deals are not reached, Health Secretary Robert F. Kennedy Jr. will be tasked with developing a rule tying the price the U.S. pays for medications to lower prices paid by other countries. The nation's pharmaceutical lobby calls Trump's order a "bad deal" for American patients. Drugmakers argue threats to their profits could impact research to develop new drugs.